Conference Coverage
Conference Coverage
Aprocitentan reduces resistant hypertension in CKD
Aprocitentan, a novel dual endothelin antagonist, showed antihypertensive efficacy and manageable safety in people with chronic kidney disease.
Conference Coverage
Marijuana use dramatically increases risk of heart problems, stroke
The latest research indicates that smoking and inhaling cannabis increases concentrations of blood carboxyhemoglobin and tar, similar to the...
Conference Coverage
Drug-coated balloon beats conventional angioplasty for high-risk patients with in-stent restenosis
This device is a U.S. FDA–designated breakthrough device, “and this pivotal trial will be the primary evidence used to support FDA approval.”
Conference Coverage
Drug-eluting resorbable scaffold beats angioplasty for infrapopliteal artery disease
“If this technology is approved by the FDA, it will provide a new option for our patients with very difficult-to-treat disease, which will provide...
Conference Coverage
No benefit of colchicine after stroke, TIA: CHANCE-3
“We require randomized trials with longer follow-up prior to abandoning this potential treatment.”
Conference Coverage
Low-risk TAVR studies: Divergent long-term results
“Cardiovascular mortality occurred at a rate of about 1% per year with both therapies, strokes at the rate of 1% per year with both therapies, and...
Conference Coverage
Trilogy TAVR safe, effective in aortic regurgitation
One-year mortality rate of 7.8% reported.
Conference Coverage
How clinicians can prepare for and defend against social media attacks
Conference Coverage
Common meds link to sudden cardiac arrest in type 2 diabetes
“If the patient has type 2 diabetes, then maybe it’s better to avoid some of these medications and try and cope without them, or at least find an...
Conference Coverage
Antidepressants ‘don’t blunt’ semaglutide and weight loss
“Semaglutide 2.4 mg provides an effective treatment option for weight management, regardless of antidepressant use at baseline.”
Conference Coverage
Trials say start sacubitril-valsartan in hospital in HF with ‘below normal’ LVEF
The risk-reduction benefit reached 41% among the overwhelming majority of patients with a left ventricular ejection fraction.